Breast cancer (BC) has been a target for immunotherapy for decades—from the clinical success of treating HER2 + BC with the monoclonal antibody Trastuzumab [1] to the approval of the PD-L1 inhibitor atezolizumab for triple-negative BC (TNBC) in 2019 [2]. This evidence concerns the gene CD274 and breast carcinoma.